October 18, 2011

Alvine Pharmaceuticals Reports Positive Results in Phase 2a Trials

Alvine Pharmaceuticals this wekk announced that the Celiac Disease Phase 2a Trial of ALV003 has shown positive results and marks a big step forward in developing a treatment for the autoimmune condition.

The study found after the second phase of the trial that the small intestinal mucosal injury was substantially lower in the group of patients who took ALV003 compared with a group who took placebos. Phase 2b of the trial is currently in the works and will begin in 2012.